Form 4: Lale White, Director at Cardiff Oncology, Reports Stock Option Grant
SEC Form 4
Director Lale White reports acquisition of stock options in Cardiff Oncology.
Summary
- Lale White, a director of Cardiff Oncology, Inc. (CRDF), filed a Form 4 with the SEC.
- The filing reports a transaction that occurred on June 27, 2024.
- White acquired 29,700 stock options with an exercise price of $2.33.
- The options become exercisable on June 27, 2025, and expire on June 27, 2034.
- Following the reported transaction, White directly owns 146,974 shares of Cardiff Oncology.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing reporting stock option grants, which can be seen as a positive sign of alignment between management and shareholders, but doesn't provide strong positive or negative signals.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider transactions and provides insight into the compensation structure and equity ownership of Cardiff Oncology's directors.
Stakeholder Impact
- The stock option grant could potentially incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/27/2024 | Date of stock option acquisition |
| 06/27/2025 | Date stock options become exercisable |
| 06/27/2034 | Expiration date of stock options |
| 07/01/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.